Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | LIPA | P38571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133229 | 0.80 | GAA (0.38) | GAATDP1SMN1; SMN2KDM4EABL1 | |
| SCHEMBL670427 | 0.80 | GAA (0.38) | GAATDP1SMN1; SMN2KDM4EABL1 | |
| SCHEMBL670428 | 0.80 | GAA (0.38) | GAATDP1SMN1; SMN2KDM4EABL1 | |
| SCHEMBL133236 | 0.79 | LIPA (0.30) | LIPA | |
| SCHEMBL6476226 | 0.74 | SMN1; SMN2 (0.41) | GAASMN1; SMN2KDM4ELMNAMAPT | |
| SCHEMBL16841453 | 0.74 | SMN1; SMN2 (0.41) | GAASMN1; SMN2KDM4ELMNAMAPT | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL5661 | 0.74 | — | — | |
| SCHEMBL9797557 | 0.74 | SMN1; SMN2 (0.50) | GAATDP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL28418543 | 0.74 | SMN1; SMN2 (0.50) | GAATDP1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL383436 | 0.74 | SMN1; SMN2 (0.50) | GAATDP1SMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2008524280-A | — | — | 2008-07-10 | — | — | JP | claimed |
| EP-1831158-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-7253282-B2 | Hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | claimed |
| WO-2006066779-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| EP-1831158-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-7253282-B2 | Hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2006066779-A1 | NOVEL CYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135601-A1 | Novel hexafluoroisopropanol substituted cyclohexane derivatives | NR1H3, NR1H2, NR1I2 | GAA 2701/4885TDP1 4479/4885SMN1; SMN2 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.